FREELITE HUMAN KAPPA AND LAMBDA FREE DIAGNOSTIC TEST KITS FOR USE ON THE ROCHE COBAS INTEGRA 400/400 PLUS ANALYZER KIT
K070900 · The Binding Site, Ltd. · DFH · Nov 30, 2007 · Immunology
Device Facts
Record ID
K070900
Device Name
FREELITE HUMAN KAPPA AND LAMBDA FREE DIAGNOSTIC TEST KITS FOR USE ON THE ROCHE COBAS INTEGRA 400/400 PLUS ANALYZER KIT
Applicant
The Binding Site, Ltd.
Product Code
DFH · Immunology
Decision Date
Nov 30, 2007
Decision
SESE
Submission Type
Traditional
Regulation
21 CFR 866.5550
Device Class
Class 2
Indications for Use
The FREELITE™ Human Kappa Free kit is intended for the quantitation of Kappa free light chains in serum on the Roche COBAS INTEGRA 400 and 400plus. Measurement of light chains aids in the diagnosis and monitoring of multiple myeloma, lymphocytic neoplasms, Waldenstrom’s macroglobulinemia, amyloidosis, light chain deposition disease and connective tissue diseases such as systemic lupus erythematosus in conjunction with other laboratory and clinical findings. The FREELITE™ Human Lambda Free kit is intended for the quantitation of Lambda free light chains in serum on the Roche COBAS INTEGRA 400 and 400plus. Measurement of light chains aids in the diagnosis and monitoring of multiple myeloma, lymphocytic neoplasms, Waldenstrom’s mac疗globulinemia, amyloidosis, light chain deposition disease and connective tissue diseases such as systemic lupus erythematosus in conjunction with other laboratory and clinical findings.
Device Story
In vitro diagnostic kit for quantitative measurement of human Kappa and Lambda free light chains in serum; utilizes polyclonal monospecific antibodies coated onto polystyrene latex particles. Operates via turbidimetric assay on Roche COBAS INTEGRA 400/400plus analyzers. Sample mixed with antibody reagent in cuvette; antigen-antibody reaction forms insoluble immune complexes; light scatter measured as decrease in intensity of incident beam. Amount of immune complex proportional to antigen concentration; results derived from calibration curve. Used in clinical laboratory settings by trained personnel. Output aids clinicians in diagnosis and monitoring of plasma cell dyscrasias and related conditions. Benefits include rapid, automated quantification of free light chains to support clinical decision-making.
Clinical Evidence
No clinical data provided; substantial equivalence is based on bench testing and performance validation of the assay on the specified analyzer platform.
Indicated for the quantitation of kappa and lambda free light chains in serum to aid in the diagnosis and monitoring of multiple myeloma, lymphocytic neoplasms, Waldenstrom's macroglobulinemia, amyloidosis, light chain deposition disease, and connective tissue diseases (e.g., systemic lupus erythematosus) in patients requiring clinical laboratory assessment.
Regulatory Classification
Identification
An immunoglobulin (light chain specific) immunological test system is a device that consists of the reagents used to measure by immunochemical techniques both kappa and lambda types of light chain portions of immunoglobulin molecules in serum, other body fluids, and tissues. In some disease states, an excess of light chains are produced by the antibody-forming cells. These free light chains, unassociated with gamma globulin molecules, can be found in a patient's body fluids and tissues. Measurement of the various amounts of the different types of light chains aids in the diagnosis of multiple myeloma (cancer of antibody-forming cells), lymphocytic neoplasms (cancer of lymphoid tissue), Waldenstrom's macroglobulinemia (increased production of large immunoglobulins), and connective tissue diseases such as rheumatoid arthritis or systemic lupus erythematosus.
Submission Summary (Full Text)
{0}
1
# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY
A. 510(k) Number:
k070900
B. Purpose for Submission:
New analyzer
C. Measurand:
Immunoglobulins, Kappa (κ) free light chains and Lambda (λ) free light chains
D. Type of Test:
Quantitative, Nephelometry or turbidimetry
E. Applicant:
The Binding Site, Ltd.
F. Proprietary and Established Names:
FREELITE™ Human Kappa Free Kit for use on Roche COBAS® INTEGRA 400/400plus
FREELITE™ Human Lambda Free Kit for use on Roche COBAS® INTEGRA 400/400plus
G. Regulatory Information:
1. Regulation section:
21 CFR § 866.5550, Immunoglobulin (light chain specific) immunological test system
2. Classification:
Class II
3. Product codes:
DFH - Kappa, antigen, antiserum, control
DEH - Lambda, antigen, antiserum, control
4. Panel:
Immunology (82)
H. Intended Use:
1. Intended use(s):
The FREELITE™ Human Kappa Free kit is intended for the quantitation of Kappa free light chains in serum on the Roche COBAS INTEGRA 400 and 400plus. Measurement of light chains aids in the diagnosis and monitoring of multiple myeloma, lymphocytic neoplasms, Waldenstrom’s macroglobulinemia, amyloidosis, light chain deposition disease and connective tissue diseases such as systemic lupus erythematosus in conjunction with other laboratory and clinical findings.
The FREELITE™ Human Lambda Free kit is intended for the quantitation of Lambda free light chains in serum on the Roche COBAS INTEGRA 400 and 400plus. Measurement of light chains aids in the diagnosis and monitoring of multiple myeloma, lymphocytic neoplasms, Waldenstrom’s macroglobulinemia, amyloidosis, light chain deposition disease and connective tissue diseases such as systemic lupus erythematosus in conjunction with other laboratory and clinical findings.
{1}
2. Indication(s) for use:
Same as Intended use.
3. Special conditions for use statement(s):
For prescription only.
4. Special instrument requirements:
Roche COBAS® INTEGRA 400/400plus
I. Device Description:
The FREELITE™ Human Kappa and Lambda Free kit contains polyclonal monospecific antibody coated onto polystyrene latex, a standard, two controls (high and low polyclonal kappa or lambda free light chain), and supplementary reagent.
J. Substantial Equivalence Information:
1. Predicate device name(s):
FREELITE™ Human Kappa Free Kit for use on Dade Behring Nephelometer™ II
FREELITE™ Human Lambda Free Kit for use on Dade Behring Nephelometer™ II
2. Predicate K number(s):
k010440 (Kappa)
k010441 (Lambda)
3. Comparison with predicate:
| Similarities | | |
| --- | --- | --- |
| Item | Device | Predicate |
| Indication for Use | Measurement of light chains aids in the diagnosis and monitoring of multiple myeloma, lymphocytic neoplasms, Waldenstrom’s macroglobulinemia, amyloidosis, light chain deposition disease and connective tissue diseases such as systemic lupus erythematosus in conjunction with other laboratory and clinical findings | Same |
| Controls | Human sera containing polyclonal free light chain, in stabilized liquid form, contain 0.099% sodium azide, 0.1% EACA, 0.01% benzamidine. Packaged in glass vials | Same |
| Stability/ storage of unopened reagent | 2-8°C until expiry date | Same |
| Differences | | |
| --- | --- | --- |
| Item | Device | Predicate |
| Instrument | Roche COBAS INTEGRA 400 and 400plus | Dade Behring Nephelometer II (BN™ II) |
| Technology | Turbidimetry | Nephelometry |
| Assay times | 8.3 minutes | 18 minutes |
{2}
| Differences | | |
| --- | --- | --- |
| Item | Device | Predicate |
| Cuvettes | Disposable | Washable |
| Sample matrix | Serum | Serum and urine |
| Sample dilution | 1:10 | 1:100 |
| Kappa or Lambda Latex Reagent | Supplied in Nalgene plastic bottles. Transferred to C-Pack prior to assay. | Supplied in Nalgene plastic bottles. No transfer prior to assay. |
| Supplementary Reagent | Type 116 Latex buffer containing Sodium Azide (NaN_{3}) 0.099%. Type 265 PEG solution can be added for optimizing reaction if required. Supplied in Nalgene plastic bottles. Transferred to C-Pack prior to assay. | Type 49 Distilled water containing Sodium Azide (NaN_{3}) 0.099%. Type 265 PEG solution can be added for optimizing reaction if required. Packaged in glass vials. |
| Opened reagent Storage/ stability | 2-8°C up to 1 month | 2-8°C up to 3 months |
| Measuring range | κ: 2.9 – 127 mg/L (1:10)
λ: 5.2 – 139 mg/L (1:8) | κ: 5.9 – 190 mg/L (1:100)
λ: 8.1 – 260 mg/L (1:100) |
| Sensitivity (serum) | κ: 0.6 mg/L (1:2)
λ: 1.3 mg/L (1:2) | κ: 0.3 mg/L (1:5)
λ: 0.4 mg/L (1:5) |
| Linearity | κ: y = 1.003x-0.937, r = 0.99
λ: y = 1.004x-1.123, r = 1.0 | κ: y = 0.98x+0.83, r = 0.99
λ: y = 0.99x-0.63, r = 1.0 |
K. Standard/Guidance Document Referenced (if applicable):
CLSI (NCCLS) EP5-A: Evaluation of Precision Performance of Clinical Chemistry Approved Guideline.
L. Test Principle:
The concentration of a soluble antigen is nephelometrically or turbidimetrically measured by the addition of the test sample to a solution containing the appropriate antibody in a reaction vessel or cuvette. A beam of light is passed through the cuvette and as the antigen-antibody reaction proceeds, the light passing through the cuvette is scattered increasingly as insoluble immune complexes are formed. The antibody in the cuvette is in excess so the amount of immune complex formed is proportional to the antigen concentration. In nephelometry the light scatter is monitored by measuring the light intensity at an angle away from incident light, whilst in turbidimetry light scatter is monitored by measuring the decrease in intensity of the incident beam of light. A series of calibrators of known antigen concentration are assayed initially to produce a calibration curve of measured light scatter versus antigen concentration. Samples of unknown antigen concentration can then be assayed and the results read from the calibration curve.
The sensitivity of nephelometric or turbidimetric assays can be increased by the use of particle enhancement. This entails linking the antibody to a suitably sized particle that increases the relative light-scattering signal of the antigen-antibody reaction.
{3}
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Precision/Reproducibility:
The study was carried out by testing three samples with different concentrations of kappa or lambda light chains using three different reagent lots on one analyzer. The study was performed over 21 working days, with two runs per day. Results are summarized below:
| Kappa Precision | Within run | | Between-run | | Between-day | | Total Precision | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | SD | %CV | SD | %CV | SD | %CV | SD | %CV |
| Low (mean 5.99 mg/L) | 0.35 | 5.8 | 0.16 | 2.7 | 0.22 | 3.6 | 0.44 | 7.4 |
| Medium (mean 18.72 mg/L) | 0.40 | 2.1 | 0.51 | 2.7 | 0.60 | 3.2 | 0.88 | 4.7 |
| High (mean 95.64 mg/L) | 1.38 | 1.4 | 1.68 | 1.8 | 2.01 | 2.1 | 2.97 | 3.1 |
| | | | | | | | | |
| Lambda Precision | Within run | | Between-run | | Between-day | | Total Precision | |
| | SD | %CV | SD | %CV | SD | %CV | SD | %CV |
| Low (mean 7.72 mg/L) | 0.17 | 2.3 | 0.19 | 2.5 | 0.29 | 3.7 | 0.39 | 5.0 |
| Medium (mean 27.0 mg/L) | 0.18 | 0.7 | 0.21 | 0.8 | 0.42 | 1.5 | 0.50 | 1.9 |
| High (mean 99.2 mg/L) | 0.72 | 0.7 | 0.73 | 0.7 | 1.60 | 1.6 | 1.90 | 1.9 |
b. Linearity/assay reportable range:
Linearity was confirmed using serial dilutions of polyclonal samples. The regression plot equations where $\mathbf{y}$ is the measured level of free chain concentration and $\mathbf{x}$ the theoretical concentration were:
$$
y = 1.003x - 0.937 \text{ (mg/L)}, r = 0.99 \text{ for } \kappa \text{ chains}
$$
$$
y = 1.004x - 1.123 \text{ (mg/L)}, r = 1.00 \text{ for } \lambda \text{ chains}
$$
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
No reference standards are available for these analytes. A calibrator and two controls are provided with each kit. No changes were made from previous cleared submission.
On-board stability studies were tested at 0, 4, 8, 13, 17, 24, 31, 38 day intervals. Stability results over the testing period meet the acceptance criteria of $\pm 20\%$ differences.
d. Detection limit:
Analytical sensitivity was determined by assaying ten replicates of two samples with concentrations close to the lowest calibration points. The analytical sensitivity claims were: $0.6 \mathrm{mg} / \mathrm{L}$ for kappa and $1.3 \mathrm{mg} / \mathrm{L}$ for lambda.
e. Analytical specificity:
Interference study: the table below shows common substances that could interfere with this method. Samples were run in triplicate. Minimum interferences were observed except for $15.5\%$ difference with Rheumatoid factor on kappa antiserum. The package insert states the information below.
{4}
5
| Interferent | Concentration | % Difference | |
| --- | --- | --- | --- |
| | | κ (15 mg/L) | λ (18 mg/L) |
| Bilirubin | 200.0 mg/L | -9.4 | -1.7 |
| Haemoglobin | 5.7 g/L | 8.2 | 3.8 |
| Intralipid | 0.2% | 1.3 | |
| | 0.5% | | -1.9 |
| Rheumatoid factor | 320.0 I.U. | 15.5 | |
| | 480.0 I.U. | | 3.3 |
f. Assay cut-off:
Refer to Expected values.
2. Comparison studies:
a. Method comparison with predicate device:
A total of 132 serum samples were tested on the Freelite Kappa and Lambda Roche Cobas Integra 400/400plus and Freelite Kappa and Lambda Dade Behring BNII assays. Fifty (50) samples were normal adult sera and 82 samples were abnormal adult sera (58 known/suspected multiple myeloma (<80 mg/dL to >1000 mg/dL) and 24 systemic lupus erythematosus). The differences observed between the two assays were likely due to different test parameters and kinetics of reaction. The data including regression analysis results were as follows:
| Samples | Kappa | Lambda |
| --- | --- | --- |
| Normal Sera (n = 50) | | |
| Range (mg/L) | 5-24 mg/L | 3-19 mg/L |
| Deming regression | y=0.932x + 1.472 | y=1.08x -1.09 |
| R² | R²=0.9168 | R²=0.9351 |
| Clinical Sera (n = 82) | | |
| Range (mg/L) | 0.4-1,900 mg/L | 1-18,700 mg/L |
| Deming regression | y=0.90x + 23.54* | y=0.892x + 50.06 |
| R² | 0.9316 | 0.9673 |
*Two markedly high monoclonal values (5000 and 120000 mg/L) were excluded from calculation.
b. Matrix comparison:
Not applicable,
3. Clinical studies:
a. Clinical Sensitivity:
Not applicable.
b. Clinical specificity:
Not applicable.
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable.
4. Clinical cut-off:
Not applicable.
5. Expected values/Reference range:
The reference range table provided below were from 282 normal subjects aged
{5}
from 20 – 90 years which were assayed using Binding Site FREELITE Kappa and Lambda Free kits on BN II™ (Katzmann, JA et al. 2002 Clin Chem 48: 1437 – 1444).
| Normal adult serum | Mean conc. | Median conc. | 95^{th} percentile range |
| --- | --- | --- | --- |
| Free Kappa | 8.36 (mg/L) | 7.30 (mg/L) | 3.30 - 19.40 (mg/L) |
| Free Lambda | 13.43 (mg/L) | 12.40 (mg/L) | 5.71 - 26.30 (mg/L) |
| | Mean | Median | Total range |
| Kappa/Lambda Ratio | 0.63 | 0.60 | 0.26 - 1.65 |
In addition, the package insert includes the following statements:
1.) “The ranges provided have been obtained from a limited number of samples and are intended for guidance purposes only. Wherever possible it is strongly recommended that local ranges are generated.”
2.) “In order to demonstrate equivalence of the normal range obtained with the BNII and INTEGRA assays, 50 normal samples from UK donors aged 20 – 60 years were assayed on both BN and INTEGRA FREELITE kits”. Results of regression analysis were:
Kappa assay
(INTEGRA) = 0.932(BNII) + 1.472, R² = 0.9168;
Lambda assay
(INTEGRA) = 1.08(BNII) – 1.09, R² = 09351
N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
O. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.
